Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

BACKGROUND: Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c(+) myeloid dendritic cells (mDCs; cDC2) and plasmacytoid DCs (pDC...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., Gerritsen, Winald R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854814/
https://ncbi.nlm.nih.gov/pubmed/31727154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0787-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia